Advertisement
This review is available at website: www.scimitarequity.com.
VioQuest Pharmaceuticals is a New Jersey-based biotechnology companydedicated to becoming a recognized leader in the successful development ofnovel drug therapies targeting both the molecular basis of cancer and sideeffects of treatment. VioQuest's oncology portfolio includes: Xyfid(TM) (1%uracil topical), for the treatment and prevention of Hand-Foot Syndrome, acommon side effect from certain chemotherapy treatments, and to treat dry skinconditions and manage the burning and itching associated with variousdermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitorof Akt activation; and Lenocta(TM) (sodium stibogluconate), an inhibitor ofcertain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B.Further information about VioQuest can be found at: www.vioquestpharm.com
Advertisement
Scimitar Equity, LLC provides sponsored equity research of emerginghealthcare companies for the investing communities. We certify that all theviews expressed in this review, accurately reflect our personal views aboutVioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP) and its or theirsecurities. No part of our compensation was, is, or will be, directly orindirectly, related to the specific recommendations or views contained in thisreview and we will not have any investment banking relationships or personalinvestment in any sponsored company. Investors are advised that this analysisand review is issued solely for informational purposes and is not to beconstrued as an offer to sell or the solicitation of an offer to buy.Scimitar was paid for preparing this review. This analysis and review doesnot have regard to the specific investment objectives, financial situation andthe information contained herein is based on sources that we believe to bereliable but is not guaranteed by us as being accurate and does not purport tobe a complete statement or summary of the available data. Any opinionsexpressed are statements of our own judgment as of the date of publication andare subject to change without notice. Please read all our importantdisclosures.
SOURCE Scimitar Equity, LLC
